Thirdly, STVNA provides substantial neuroprotection through cerebral perfusion-independent effects and in permanent MCAO models of stroke, unlike tirilazad (a perfusion-dependent neuroprotective agent) [27] and anti-intercellular adhesion molecule-1 antibody [28], which have only been proven effective in tMCAO. Here, ICAM1 is linked to stroke disorder.